中国药房2016，Vol.27Issue(20)：2756-2758,3.DOI:10.6039/j.issn.1001-0408.2016.20.06
我院108例化疗致Ⅳ度骨髓抑制的晚期乳腺癌患者用药合理性分析Δ
Retionality Analysis of Drug Use in 108 Advanced Breast Cancer Patients with Grade Ⅳ Myelosupression Induced by Chemotherapy from Our Hospital
摘要
Abstract
OBJECTIVE:To provide reference for clinical rational drug use in advanced breast cancer patients with grade Ⅳmyelosupression induced by chemotherapy. METHODS:108 advanced breast cancer patients with grade Ⅳ myelosupression in-duced by chemotherapy in our hospital from July 2014 to June 2015 were retrospectively analyzed on the characteristics of myelosu-pression and the reasonability of chemotherapy reguneb and adjuvant drug for myelosupression. RESULTS:The incidence of gradeⅣ myelosupression induced by chemotherapy in advanced breast cancer patients was 8.3%,chiefly manifesting as grade Ⅳ neutro-penia(94.4%). The chemotherapy regimens which induced grade Ⅳ myelosupression were mainly docetaxel+epirubicin,docetaxel, vinorelbine+lobaplatin;irrational chemotherapy plan mainly shows irrational pretreatment of chemotherapy drug (32 cases, 91.4%);irrational therapy of myelosupression mainly manifested as rophylactic use of antimicrobials without indication,unsuitable choice of antibiotics(29 cases for each,36.2% for each). CONCLUSIONS:The use of drugs used in advanced breast cancer pa-tients with grade Ⅳ myelosupression induced by chemotherapy is basically rational,yet it is far from perfect in pretreatment of che-motherapy drug and therapy for gradeⅣmyelosupression,which should be further improved.关键词
化疗/乳腺癌/晚期/Ⅳ度骨髓抑制/合理用药Key words
Chemotherapy/Breast cancer/Advanced/GradeⅣmyelosupression/Rational drug use分类
医药卫生引用本文复制引用
杜娟,赵秀莉,张文周,王毅刚..我院108例化疗致Ⅳ度骨髓抑制的晚期乳腺癌患者用药合理性分析Δ[J].中国药房,2016,27(20):2756-2758,3.基金项目
河南省医学科技攻关计划基金资助项目 （）
